Medulloblastoma in adults: clinical characteristics and treatment

• Published in: Cancer treatment reviews Vol. 25; no. 1; pp. 3 - 12
• Main Authors: Brandes, A.A., Palmisano, V., Monfardini, S.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01.02.1999; Elsevier
• Subjects: Actuarial Analysis; Adolescent; Adult; adults; Aged; Antineoplastic agents; Biological and medical sciences; Cerebellar Neoplasms - mortality; Cerebellar Neoplasms - pathology; Cerebellar Neoplasms - therapy; Chemotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Cranial Irradiation; follow-up; Humans; Medical sciences; Medulloblastoma; Medulloblastoma - mortality; Medulloblastoma - pathology; Medulloblastoma - therapy; Middle Aged; Neoplasm Recurrence, Local - mortality; pathology; Pharmacology. Drug treatments; Premedication; Prognosis; radiotherapy; Radiotherapy, Adjuvant; recurrences; Retrospective Studies; review; Salvage Therapy; Survival Analysis; Survival Rate; therapy; Treatment Outcome; recurrences; follow-up; pathology; Medulloblastoma; therapy; review; adults; radiotherapy; chemotherapy; Antineoplastic agent; Human; Nervous system diseases; Relapse; Prognosis; Neurospongioma; Adjuvant treatment; Malignant tumor; Review; Radiotherapy; Malignant glioma; Treatment; Surgery; Central nervous system disease; Diagnosis; Predictive factor

Long-term survival is possible in adults with medulloblastoma with rates of approximately 50–60% at 5 years, and 40–50% at 10 years. As the literature data are based on retrospective studies, treatments are neither randomized nor uniform, however, some treatment cornerstones have been identified. Th...